BIOMAT Database Logo BIOMAT Database Logo

Mapping peptide antagonist binding sites of the human V1a and V2 vasopressin receptors. 1998

B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Unité INSERM 469 CCIPE, Montpellier, France.

UI MeSH Term Description Entries
D010449 Peptide Mapping Analysis of PEPTIDES that are generated from the digestion or fragmentation of a protein or mixture of PROTEINS, by ELECTROPHORESIS; CHROMATOGRAPHY; or MASS SPECTROMETRY. The resulting peptide fingerprints are analyzed for a variety of purposes including the identification of the proteins in a sample, GENETIC POLYMORPHISMS, patterns of gene expression, and patterns diagnostic for diseases. Fingerprints, Peptide,Peptide Fingerprinting,Protein Fingerprinting,Fingerprints, Protein,Fingerprint, Peptide,Fingerprint, Protein,Fingerprinting, Peptide,Fingerprinting, Protein,Mapping, Peptide,Peptide Fingerprint,Peptide Fingerprints,Protein Fingerprint,Protein Fingerprints
D006727 Hormone Antagonists Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. Antagonists, Hormone
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D017483 Receptors, Vasopressin Specific molecular sites or proteins on or in cells to which VASOPRESSINS bind or interact in order to modify the function of the cells. Two types of vasopressin receptor exist, the V1 receptor in the vascular smooth muscle and the V2 receptor in the kidneys. The V1 receptor can be subdivided into V1a and V1b (formerly V3) receptors. Antidiuretic Hormone Receptors,Receptors, V1,Receptors, V2,V1 Receptors,V2 Receptors,Vasopressin Receptors,8-Arg-Vasopressin Receptor,Antidiuretic Hormone Receptor,Antidiuretic Hormone Receptor 1a,Antidiuretic Hormone Receptor 1b,Arginine Vasopressin Receptor,Argipressin Receptor,Argipressin Receptors,Receptor, Arginine(8)-Vasopressin,Renal-Type Arginine Vasopressin Receptor,V1 Receptor,V1a Vasopressin Receptor,V1b Vasopressin Receptor,V2 Receptor,Vascular-Hepatic Type Arginine Vasopressin Receptor,Vasopressin Receptor,Vasopressin Receptor 1,Vasopressin Type 1A Receptor,Vasopressin V1a Receptor,Vasopressin V1b Receptor,Vasopressin V2 Receptor,Vasopressin V3 Receptor,8 Arg Vasopressin Receptor,Hormone Receptor, Antidiuretic,Hormone Receptors, Antidiuretic,Receptor, Antidiuretic Hormone,Receptor, Arginine Vasopressin,Receptor, Argipressin,Receptor, V1,Receptor, V2,Receptor, Vasopressin,Receptor, Vasopressin V1b,Receptor, Vasopressin V3,Receptors, Antidiuretic Hormone,Receptors, Argipressin,Renal Type Arginine Vasopressin Receptor,V1b Receptor, Vasopressin,Vascular Hepatic Type Arginine Vasopressin Receptor,Vasopressin Receptor, V1b
D019204 GTP-Binding Proteins Regulatory proteins that act as molecular switches. They control a wide range of biological processes including: receptor signaling, intracellular signal transduction pathways, and protein synthesis. Their activity is regulated by factors that control their ability to bind to and hydrolyze GTP to GDP. EC 3.6.1.-. G-Proteins,GTP-Regulatory Proteins,Guanine Nucleotide Regulatory Proteins,G-Protein,GTP-Binding Protein,GTP-Regulatory Protein,Guanine Nucleotide Coupling Protein,G Protein,G Proteins,GTP Binding Protein,GTP Binding Proteins,GTP Regulatory Protein,GTP Regulatory Proteins,Protein, GTP-Binding,Protein, GTP-Regulatory,Proteins, GTP-Binding,Proteins, GTP-Regulatory

Related Publications

B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.
July 1997, European journal of pharmacology,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors.
December 2001, Journal of computer-aided molecular design,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Vasopressin receptors V1a and V2 are not osmosensors.
August 2015, Physiological reports,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Mapping the binding site of arginine vasopressin to V1a and V1b vasopressin receptors.
February 2007, Molecular endocrinology (Baltimore, Md.),
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
January 2007, Cardiovascular drug reviews,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
January 1998, Naunyn-Schmiedeberg's archives of pharmacology,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
[Functional expression of vasopressin receptors V1a and V2 along the mammalian nephron].
January 1995, Comptes rendus des seances de la Societe de biologie et de ses filiales,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
[Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
October 1999, Nihon yakurigaku zasshi. Folia pharmacologica Japonica,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Molecular cloning and expression of rat V1a and V2 arginine vasopressin receptors.
April 1993, Regulatory peptides,
B Mouillac, and S Phalipou, and N Cotte, and M N Balestre, and M Hibert, and M Manning, and C Barberis
Alterations of renal vasopressin V1A and V2 receptors in spontaneously hypertensive rats.
February 2003, Pharmacology,
Copied contents to your clipboard!